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Background: Synovial sarcoma (SS) is a rare tumor, with dismal survival when metastatic. The role of adjuvant
chemotherapy is debated. New prognostic and predictive factors are needed.
Methods: We reviewed patients with localized SS; SS18-SSX fusion transcript presence was confirmed by FISH and
RT-PCR. Expression of CXCR4, IGF-1R and Ezrin were evaluated by immunohistochemistry.
Results: Tumor samples from 88 SS patients (45 female; 43 male) with median age 37 years (range 11–63) were
selected. The size of the lesion was > 5 cm in 68% of patients and 34% of cases presented biphasic histotype. All
patients underwent surgery, 56% adjuvant radiotherapy (RT), 65% adjuvant chemotherapy. A positive stain for IGF-1R
was detected in 55 patients, with nucleus expression in 21 patients. CXCR4 was expressed in 74 patients, nuclear
pattern in 31 patients. 80 SS were positive to Ezrin, 48 had cytoplasmatic location, 32 membrane location. With a
median follow-up of 6 years (1–30 years), the 5-year overall survival (OS) was 70% (95% CI 60–81). 5-year OS was 63%
(95% CI 41-85%) for patients with positive IGF-1R/nuclear expression, and 73% (95% CI 61-85%; P = 0.05) in negative
patients. 5-year OS was 47% (95% CI 27-66%) in patients with positive CXCR4/nuclear staining, and 86% (95% CI 76-96%,
P = 0.0003) in negative cases. No survival difference was found according to Ezrin expression. By multivariate analysis,
nuclear expression of CXCR4 and IGF-1R was confirmed independent adverse prognostic factor for SS patient survival
linked to the use of chemotherapy.
Conclusions: Our findings have important potential implications demonstrating that together with clinical prognostic
factors such as radiotherapy and age, CXCR4 and IGF-1R negatively influences survival in patients with localized SS. We
believe that further studies addressed to the effects of CXCR4 and IGF-1R inhibitors on cell viability and function are
needed to plan new and more appropriate SS treatments.
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Synovial sarcoma (SS) comprises approximately 8% of all
soft tissue sarcomas (STSs), with the lower limbs being
the most common site of primary disease [1]. Although
relatively rare, SS is the third most common extremity
STS. It affects mostly young adults, with a median age of
35 years [2]. Three histologic subtypes of SS are described:* Correspondence: emanuela.palmerini@ior.it
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unless otherwise stated.monophasic, entirely composed of spindle cells; biphasic,
composed of both spindle cells and epithelial cells; and
poorly differentiated subtypes [3]. Synovial sarcoma con-
tains a characteristic translocation (X;18)(p11;q11), repre-
senting the fusion of SYT on chromosome 18 with either
SSX1, SSX2, or rarely SSX4 on chromosome X [4]. The
resulting fusion genes appear to be mutually exclusive and
concordant in primary and metastatic tumors [5]. In a pre-
vious series of 250 patients with SS dating back to 1976,
we demonstrated that stage, size, age, and histologic sub-
type were independent factors for event free survival [6].
Also, this study provided further evidence that adjuvantal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and should always be performed in large lesions [7]. Other
factors, such as surgical margins, p53 overexpression,
Ki-67 proliferative index, and SYT-SSX fusion type, have
been identified [8-13]. The role of adjuvant chemotherapy
in SS is debated. In the metastatic setting, a high response
rate to ifosfamide-based therapy has been reported (40%-
70%) [14,15]. Therefore, adjuvant chemotherapy is fre-
quently used for localized disease [1,16]. A previous genetic
study [17] identified a hypoxia-induced metastatic profile
in pleomorphic high-grade STSs providing information for
selection of high-risk tumors. Multiple regulators of signal-
ling pathways including EGF and FGF receptors, members
of the Hedgehog (Hh) family, genes involved in retinoic
and Notch pathways, and in chromatin remodelling were
found up regulated in SS [18].
Chemokine receptor 4 (CXCR4) is a seven-transmembrane
G protein-coupled chemokine receptor and it is the che-
mokine receptor most commonly expressed in tumor
cells, with increased expression in presence of metastatic
disease in many tumors including bone and soft tissue
sarcomas [19,20]. CXCR4 has also been demonstrated to
be involved in cell migration and invasion, as well as
angiogenesis.
Insulin growth factor-1 receptor (IGF-1R) is involved
in IGF-II signalling and down-regulation or inhibition of
this receptor leads to increased numbers of apoptotic
cells in SS18–SSX-transformed cells and SS cell lines
[21]. In addition, a study that investigated IGF-1R ex-
pression in 35 SS found that there was an association
between IGF-1R expression and an increased incidence
in lung metastasis [22].
Ezrin is a membrane-cytoskeleton linker protein in-
volved in growth regulating and metastatic behaviour of
cancer cells. Our previous experience in osteosarcoma de-
tected Ezrin immunoreactivity in the majority of patients
with non-metastatic osteosarcoma of the extremity and re-
vealed that the cytoplasmatic pattern was associated with
good prognosis [23].
In order to identify a subgroup of patients with poorer
prognosis who most likely benefit from adjuvant chemo-
therapy, we selected localized chemo-naïve SS patients
from our previously studied series [6] and assessed the
prognostic role of CXCR4, IGF-1R and Ezrin by correlating
their expression with clinical and histological parameters.
Methods
Design and patients
This study is a systematic mono institutional retrospect-
ive analysis. From the previous series of 250 patients [6]
referred to our Institute between 1976–2008, we selected
patients admitted for first diagnosis; therefore, metastatic
and recurrent patients at presentation were excluded.
All patients with incomplete clinical and follow-up datawere also excluded. General informed consent to the use
of material was obtained from all adult patients or from
parents/guardians for minors from 2004.
The research protocol was approved by the ethics
committee of the Rizzoli Orthopedic Institute.
Data collection
Demographic data (age at onset, gender, follow-up dur-
ation), clinical-histological presentation (biphasic, mono-
phasic/poorly differentiated, tumor size, site), treatment
(R0/R1 resection, adjuvant chemotherapy, adjuvant radio-
therapy), and outcome (overall survival (OS), were col-
lected. Follow-up was obtained from hospital charts, or if
necessary, by a phone call.
Histology and molecular studies
The diagnosis was confirmed by pathologists with ex-
pertise in soft tissue and bone tumors, after revision of
histological slides according to histopathological and im-
munohistochemical criteria [3]. The presence of SS18
(SYT) gene rearrangement and fusion transcripts was
assessed by Fluorescence in situ hybridization (FISH)
and Reverse Transcriptase-Polymerase Chain Reaction
(RT-PCR) analysis for diagnosis confirmation.
FISH analysis
FISH was performed using the SS18(SYT) (18q11.2) VYsis
LSI Dual Color Break-apart DNA probes (Abbott Mole-
cular, Des Plaines, IL, USA) according to the manufac-
turer’s protocol. A minimum of 100 tumor cell nuclei with
intact morphology as determined by DAPI counterstaining
were counted in the previously marked neoplastic area. A
positive result was defined as the presence of a visible
translocation (separation of red and green signals > 3 sig-
nal diameters) in more than 10% of the cells [24].
RT-PCR analysis
RNA was extracted from fresh tissue using a modified
method including Trizol Reagent (Invitrogen, Carlsbad,
CA) and the column of RNeasy Mini Kit (Qiagen GmbH,
Hilden Germany). 2 μg of RNA was reverse transcribed
using High Capacity cDNA Archive Kit (Applied Biosys-
tems, Foster City, CA). The primers used for detection of
t(X;18) SS18(SYT)-SSX1 and t(X;18) SS18(SYT)-SSX2 by
PCR amplification was: forward SS18 5′GGA CAA GGT
CAG CAG TAT GGA3′; reverse primers for SSX1 5′TTG
GGT CCA GAT CTC TTA TT3′; and reverse for SSX2 5′
TTGGGTCCAGATCTCTCGTG3′ [25].
Immunohistochemistry staining
Paraffin embedded tissue from non-treated patients was
used for immunohistochemistry (IHC) analysis. The sec-
tions (4 μm thickness) were de-paraffinized by 30 mi-
nutes in dry oven at 55-60°C and 1 hour in xylene; then
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75%. After rinsing with water for 2 minutes, sections
were pre-treated with 3% hydrogen peroxide for 5 mi-
nutes and Universal Block (KPL, Inc.) for 15 minutes.
The sections were incubated for 30 minutes at room
temperature with monoclonal antibodies CXCR4 (Ab-
2074, Abcam, Cambridge, UK; 1:1000 dilution), IGF-1R
(C-20 Santa Cruz Biotechnology, Inc. CA, USA; 1:100
dilution), Ezrin (ThermoScientific, Fremont, CA, USA;
1:200 dilution).
Antibody detection was performed using UltraView
Universal DAB Detection Kit and UltraView Universal
Alkaline Phosphatase Red Detection Kit (Ventana Medical
Systems, Tucson AZ, USA). Pre-treatment for antigen re-
trieval was performed at 95°C with Tris-EDTA ph 8 for
20 minutes. Sections were counterstained with haema-
toxylin, dehydrated and mounted.
The negative control was prepared omitting the pri-
mary antibody. Positive controls included in each run
were HELA for CXCR4 and human kidney for IGF-1R
and Ezrin.
The immunoreactivity was interpreted by the percent-
age of positive cells (0 = negative, 1 = <25% of cells, 2 =
26-75% of cells, 3 = positivity of >75% of cells). All sam-
ples scored 1 to 3 were considered positive. Cytoplas-
matic, nuclear and membrane immunoreactivity was
considered for the staining distribution pattern.
Statistical analysis
The following parameters were examined for statistical
prognostic correlations: patient age, tumor size, surgical
margins, histology, use of chemotherapy, use of radiother-
apy, total expression of CXCR4, nuclear and/or mem-
brane/cytoplasm expression; total expression of IGFR1,
nuclear and/or cytoplasmatic expression. Total expression
of Ezrin, cytoplasmatic only and cytoplasmatic/membrane
expression. The following categories were compared: pa-
tients age (adolescent and young adults (AYA) with <
30 years versus adults with ≥30 years); tumor size (≤5 cm
versus >5 cm); surgical margins (adequate including wide
or radical versus inadequate including intralesional, mar-
ginal or contaminated margins, according to Enneking’s
classification) [26]; histology (biphasic versus other his-
totypes); adjuvant treatments (chemotherapy or radio-
therapy performed within 3 months after tumor excision).
Chi-square (χ2) test with Fisher’s exact p value was used to
correlate protein expression with clinical parameters.
Overall survival (OS) time was calculated from the time
of admission at our Institute to death or last follow-up
visit. All time-to-event end points were modelled using
the method of Kaplan and Meier and analysed by the
log-rank test. The results of the Cox model analysis
were reported as relative risks (RRs) and 95% confi-
dence intervals (CIs).Results
A total of 88 consecutive patients were selected. Forty-
five were female and 43 male; median age was 37 years
(range 11–63); 14 were adolescents and young adults
(AYA) ( <30 years) and 74 were adults (≥30 years). Size
of the lesion was > 5 cm in 60 patients (68%), ≤ 5 cm in
24 (27%) and unknown in 4 patients. The tumor site was
trunk in 13 cases (15%), lower extremity in 64 cases
(73%), upper extremity in 11 cases (12%). Concerning
histotypes, 30 patients (34%) had biphasic SS, 51 (58%)
monophasic SS and 7 (8%) poorly differentiated SS. All
patients underwent surgery with adequate surgical mar-
gins in 68 cases, inadequate in 18 and in 2 cases surgical
margins were unknown. Amputation was performed in
24 patients (27%). Forty-seven patients (53%) underwent
adjuvant radiotherapy (RT) and 57 (65%) chemotherapy,
27 of them (47%) preoperatively (epirubicin/adrymicin
and ifosfamide combination in 49 cases, non-ifosfamide
containing regimen in 8 cases and in 1 case the treat-
ment was unknown).
FISH and RT-PCR Analysis
By FISH analysis, all 88 SS presented SS18 (SYT) gene re-
arrangement resulting in (X;18)(p11.2;q11.2) translocation,
thus confirming the histological diagnosis. The presence
of SSX fusion transcripts was assessed on 46 frozen tissues
by RT-PCR: 28 cases presented SSX1 variant, 18 had SSX2
variant.
Immunohistochemistry
CXCR4 was positive in 74 SS (84%), 43 had a mem-
brane/cytoplasmatic staining, 31 nuclear (7 nuclear only
and 24 nuclear and cytoplasmatic) (Figure 1a,b).
A positive expression for IGF-1R was detected in 55 pa-
tients (62.5%), 34 had a membrane/cytoplasmatic staining,
21 presented nuclear positivity (5 nuclear only and 16
both nuclear and cytoplasmatic) (Figure 1c,d). No signi-
ficant difference was observed for CXCR4 and IGF-1R
proteins expression between biphasic and monophasic SS
in terms of positivity [CXCR4: biphasic: 25/30 (83%);
monophasic: 44/51 (86%); IGF-1R: biphasic: 17/30 (57%);
monophasic: 33/51 (64%)], and intracellular distribution
[nuclear CXCR4: biphasic: 8/30 (27%); monophasic: 21/51
(41%); IGF-1R: biphasic: 6/30 (20%); monophasic: 14/51
(27%)].
Nuclear expression of both CXCR4 and IGF-1R was de-
tected in 8 cases.
80 SS were positive to Ezrin (91%), 48 presented only
cytoplasmatic location while 32 had cytoplasmatic and/
or membrane staining. Interestingly, the percentage of
positive cases in biphasic was higher than in monophasic
subgroup (100% vs. 86%, exact Fisher’s test P = 0.04).
Concerning intracellular staining distribution, while bi-
phasic had exclusively Ezrin cytoplasmatic location in
Figure 1 Expression of CXCR4 and IGF-1R in synovial sarcoma. Immunohistochemical expression of CXCR4 with cytoplasmatic (a) and nuclear (b)
distribution. Immunohistochemical expression of IGF-1R with cytoplasmatic (c), and nuclear distribution (d) (IHC 20X).
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plasmatic/membrane expression in 14 /30 (47%), the dis-
tribution pattern of monophasic SS was predominantly
cytoplasmatic. In detail, 32/44 cases (73%) had only cyto-
plasmatic staining, 12/44 (27%) had both cytoplasmatic
and membrane positivity and 6 cases had localized mem-
brane reactivity.
Outcome and statistical correlations
With a median follow-up of 6 years (1–30 years), the 5-
year overall survival (OS) was 70% (95% Cl 60-81%). The
5-year OS was significantly better for young patients
(100% for AYA and 65% for adult patients, P = 0.003).
For CXCR4 and IGF-1R expression and outcome correl-
ation, the positivity in the nucleus was chosen and defined
as CXCR4/nuclear staining and IGF-1R/nuclear expression.
The 5-year OS was significantly better for patients
with negative CXCR4/nuclear staining (86% for negative
and 47% for positive patients, P = 0.0003) (Figure 2d),
and for patients with negative IGF-1R/nuclear expres-
sion (73% for negative and 63% for positive patients, P =
0.05) (Figure 2a). According, combined CXCR4/IGF-1R/
nuclear positive staining (double positive) was associated
with poorer survival (double positive: 5-year and 8-year
OS 57% (% CI 20–94) and 20% (% CI 0–52); non- double
positive: 5-year and 8-year OS 71 (% CI 60–83) and 67%
(% CI 55–73); P = 0.02).No significant correlation between Ezrin expression and
clinical variables was found (Table 1).
An increased overall survival, close to statistical sig-
nificance (p = 0.07), was documented in patients under-
going radiation therapy, while chemotherapy, surgical
margins, histologic subtype (biphasic vs. other) as well
as Ezrin expression did not have any impact on the out-
come (Table 1).
Furthermore, in 46 patients with frozen tissues avail-
able we found no difference between SSX variants. The
5-year OS was 74% (% CI 56–92) for SSX1, and 68% (%
CI 42–94; p = 0.8) for SSX2.
Finally, we performed a survival analysis in 2 sub-
groups of patients: chemotherapy treated and untreated
patients. In the first group the 5-year OS was 75% for
patients with IGF1R/nuclear negative staining versus
66% for positive patients (p = 0.9) and 90% for patients
with CXCR4/nuclear negative staining versus 32% for
positive patients (p = 0.0001) (Figure 2b,e). In the group
of untreated patients, the 5-year OS was and 85% for pa-
tients with IGF1R/nuclear negative staining versus 43%
for positive patients (P = 0.01) and 78% for patients with
CXCR4/nuclear negative staining versus 65% for positive
patients (P = 0.5) (Figure 2c,f ). After multivariate ana-
lysis nuclear expression of CXCR4, IGF-1R and use of
RT were confirmed statistically significant independent
factors for OS, while and age were not (Table 2).
Figure 2 Overall survival curves according to nuclear IGF-1R (a, b, c) and CXCR4 (d, e, f) expression (negative versus positive) for (a, d) the
whole population (n = 88), (b, e) for the patients who did receive an adjuvant treatment (n = 60), (c, f) for the patients who did not
receive an adjuvant treatment (n = 30).
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As for other high-grade malignant soft tissue tumors, the
standard treatment of SS is the wide surgical removal of
the lesion and radiotherapy [7]. Survival rate ranges from
62% to 83% in a variety of studies and better results are re-
ported for smaller tumors (<5 cm), and for those in which
negative surgical margins are achieved [6,16].
The role of adjuvant chemotherapy in SS remains
controversial and definitive conclusions have been difficult
to make in absence of histology-specific chemotherapy
protocols. Nonetheless adjuvant chemotherapy has been
employed in case of localized disease, especially in the
pediatric population [12]. With the currently available
treatments, in particular in adults and for advanced/recurrent disease [15,27], the prognosis of SS remains un-
satisfactory and there is an urgent need to identify prog-
nostic and predictive factors.
Our SS population is representative of the largest
previously published SS series [6,12] for clinical and
treatment characteristics and, most importantly, for ex-
pression of prognostic factors for overall survival. This
study includes a consecutive series of localized SS pa-
tients, treated in a referral center. In all cases the diag-
nosis of SS was confirmed by the presence of (X;18)
(p11.2;q11.2) translocation [13] and the possible prog-
nostic role of IGF-1R, CXCR4 and Ezrin was assessed
by correlating protein immunoreactivity with clinical
and histological features.








Age Adult 74 65 53-77 0.003
AYA 14 100
Size <5 cm 24 82 66-98 0.4
uk in 4 pts ≥5 cm 60 67 53-80
Margins° Adequate 68 69 57-81 0.8
Inadequate 18 76 51-100
Histology Biphasic 30 67 53-80 0.5
Other 58 76 59-93
Chemotherapy No 28 73 67-85 0.5
Yes 60 68 54-81
Radiotherapy* No 37 67 51-83 0.07
Yes 47 77 63-92
IGF-1R Negative 33 72 53-90 0.3
Positive 55 69 56-82
IGF-1R/nuclear Negative 67 73 61-85 0.05
Positive 21 63 41-85
CXCR4 Negative 14 92 76-100 0.1
Positive 74 66 54-78
CXCR4/nuclear Negative 57 86 76-100 0.0003
Positive 31 47 54-78
EZRIN Negative 8 100 0.2
Positive 80 67 55-78
EZRIN positivity
pattern
Cytoplasmatic 49 65 50-79 0.9
Cyto/membrane 31 70 52-89
AYA: adolescent and young adults; OS: overall survival; IGF-1R: insulin growth
factor-1 receptor; CXCR4: chemokine (C-X-C motif) receptor 4; uk:
°unknown in 2 pts.
*unknown in 4 pts.
Table 2 Multivariate analysis for 5-year OS







SIZE ≤5 cm 1








HR: hazard ratio; AYA: adolescent and young adults; OS: overall survival; IGF-1R:
insulin growth factor-1 receptor; CXCR4: chemokine (C-X-C motif).
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strong independent adverse prognostic factor for overall
survival. Interestingly, the meaning of the nuclear ex-
pression of the two markers was linked to the use of
chemotherapy. In fact, IGF-1R/nuclear expression was
significantly related to a poor probability of survival, but
only in patients who did not undergo adjuvant chemo-
therapy. On the contrary, CXCR4/nuclear negative ex-
pression was predictive of poor prognosis, but only in
patients who received adjuvant chemotherapy.
IGF-1R is a transmembrane receptor highly expressed
in many human cancers, including sarcomas [28]. The
implication of IGF/IGF-1R axis in SS development and
management was discussed in a study demonstrating
that SS18–SSX1 or SS18–SSX2 fusion genes up-regulate
insulin-like growth factor-2 (IGF-2) through epigenetic
mechanisms [29]. Finally, by microarray analysis, high
expression levels of the ligand IGF-2 were found in SSsamples [30], that also expressed IGF-1R [31]. In this study
we demonstrated that a high percentage of SS presented
positivity for IGF-1R, with nuclear and/or cytoplasmatic
immunostaining in both monophasic and biphasic sub-
types. As previously described, IGF-IR auto-regulates IGF-
IR gene by translocating to nucleus [32].
In our SS, as in breast and lung tumor [32,33], the sur-
vival was significantly better for patients with negative
IGF-1R/nuclear expression when compared to nuclear-
positive patients. Although this result emphasizes the im-
portance of immunostaining location, the poor-prognostic
significance of IGF-1R/nuclear expression, also confirmed
by multivariate analysis, was limited to a subgroup of pa-
tients who did not receive systemic therapy. We believe
that this may reinforce the role of IGF-1R as strong prog-
nostic factor in SS, selecting high-risk patients candidates
for adjuvant therapy.
Recently, Asmane et al. [34] suggested that the nuclear
location of IGF-1R might activate signaling pathways
demonstrating that patients with advanced sarcoma had
better progression-free and overall survival when treated
with IGF-1R antibody therapy.
In the last years there is an increasing interest on the
interaction of the cancer cells with their microenviron-
ment, mediated by the chemokine ligand CXCL12, and
its chemokine receptor 4 (CXCR4) [35]. This axis plays
critical roles in tumor progression, including promotion
of tumor cell proliferation and survival, metastasis and
angiogenesis [36]. CXCR4 is important for the prognosis
of several tumor types, including melanoma [36], colon
[37], pancreatic [38], gastric [39] cancer and STS [20].
Our results showed that CXCR4 nuclear expression was
Palmerini et al. Orphanet Journal of Rare Diseases  (2015) 10:6 Page 7 of 8an independent adverse prognostic factor for localized
SS predominantly in the group of patients who received
chemotherapy. Accordingly, D’Alterio et al. [40] demon-
strated that a high expression of CXCR4 was associated
with poor response in metastatic renal cancer patients
treated with sunitinib.
Thus, the inferior survival of SS patients with CXCR4
nuclear positivity, as compared with negative patients,
might suggest that CXCR4 is involved in mechanisms of
resistance to chemotherapy. The anti-tumor activity of a
CXCR4 antagonist has been shown in pre-clinical and
animal tumor models [41], and several clinical studies
on CXCR4 antagonists as chemosensitizer for treatment
of patients with hematological and solid tumors are un-
derway [35,42].
The role of Ezrin, a cytoskeleton linker protein that is
actively involved in regulating the growth and metastatic
capacity of cancer cells, has been reported in adult soft tis-
sue sarcoma with a direct correlation between IHC stain-
ing intensity, histological grade and infiltrative growth
pattern [43]. In our series the majority of SS were positive
to Ezrin revealing that expression and distribution pattern
of staining (cytoplasmatic/membraneous) was not as rele-
vant for prognosis as in osteosarcoma [23]. However, all 8
patients with negative Ezrin immunostaining were alive at
5 years.
Altogether, these findings, should be analyzed in the
context of older reported prognostic factors such as Ki67
and p53 [44,45], and newer ones such as CINSARC [46].
In a future scenario an high expression of Ki67, a mutated
p53, a C2 CINSARC signature (increased genomic com-
plexity), together with nuclear positivity for CXCR4 and
IGF-1R expression, could represent novel tools to stratify
SS patients for treatment.
Conclusions
Our findings have important potential implications dem-
onstrating that together with clinical prognostic factors
such as radiotherapy and age, CXCR4 and IGF-1R nu-
clear expression is a strong independent adverse prog-
nostic factor for SS patient survival, linked to the use of
chemotherapy. Based on these data, CXCR4/nuclear ex-
pression was predictive of poor prognosis in patients
who received adjuvant chemotherapy, emphasizing its
possible involvement in drug-resistance mechanisms. In
contrast, IGF-1R/nuclear expression, significantly related
to poor survival in patients who did not receive adjuvant
chemotherapy, may differentiate a subgroup of SS pa-
tients candidate to adjuvant chemotherapy.
We believe that CXCR4 antagonists, combined with
chemotherapy, could act as chemosensitizer in SS, as
suggested in other hematological and solid tumors set-
tings [35,42]. Further studies addressing the effects of
CXCR4 and IGF-1R inhibitors on cell viability andfunction are needed to plan new and more appropriate
SS treatments.
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